Background The relationship between baseline C-reactive protein (CRP) level and the
prognosis of cancer patients receiving immune checkpoint inhibitor (ICI) treatment remains …

Salivary gland cancers (SGCs) are rare, accounting for less than 5% of all malignancies of
the head and neck region, and are morphologically heterogeneous. The diagnosis is mainly …

Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-
targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent …

Salivary gland malignancies are rare neoplasms that have a broad histological spectrum
and a variety of biologic behaviors. Salivary gland malignancies are known as chemo …

Gene expression analysis enhances proper cancer subtyping, a better understanding of the
molecular characteristics of cancer, and strategies for precision medicine. However, salivary …

Abstract Background The association between Glasgow Prognostic Score (GPS) and the
modified Glasgow Prognostic Score (mGPS) and clinical outcomes in patients receiving …

Simple Summary No real-world, long-term outcomes of immunotherapy with nivolumab for
recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have …

Although several prognostic factors in nivolumab therapy have been reported in recurrent or
metastatic head and neck cancer (RM-HNC) patients, these factors remain controversial …

Introduction Tumor immunotherapy has recently emerged as a crucial focal point in
oncology treatment research. Among tumor immunotherapy approaches, tumor immune …

Salivary duct carcinoma (SDC) is an aggressive type of salivary gland carcinoma. Recently,
immunotherapies targeting immune checkpoints, including PD1, PD-L1, CTLA4, and LAG3 …